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Hirotaka Kihara, 1 Teruhisa Fujii, 3 and Masao Kobayashi 1 BACKGROUND: Anti-human neutrophil antigen (HNA)
antibodies have been implicated in the development of neonatal alloimmune neutropenia (NAN) and autoimmune neutropenia (AIN). There are many conventional assay methods that detect anti-HNA antibodies. However, a method to measure multiple samples and detect several anti-HNA antibodies simultaneously is needed.
STUDY DESIGN AND METHODS:
We developed a new method, the extracted granulocyte antigen immunofluorescence assay (EGIFA) , to analyze anti-HNA-1a, -1b, and -2 antibodies in sera. The results obtained by EGIFA were evaluated in comparison with those from several standard assay methods. Anti-HNA antibodies in serum samples from nine familial cases with suspected NAN (n 5 19) and children with suspected AIN (n 5 88) were also measured by EGIFA.
RESULTS:
The evaluation of nine serum samples with anti-HNA antibodies suggested that EGIFA demonstrated equivalent specificity and superior sensitivity to monoclonal antibody-specific immobilization of granulocyte antigens and had comparable sensitivity to the granulocyte indirect immunofluorescence test. EGIFA successfully detected anti-HNA-1a or -1b antibodies in seven of nine familial cases with suspected NAN. EGIFA detected anti-HNA antibodies in 40.9% of children with suspected AIN. Among them, isolated anti-HNA-1a or -1b antibody was detected in 4.5 or 12.5% of children, respectively, and anti-HNA-2 antibody was identified in 3.4% of children. The 30.8% (16 of 52) of children negative for anti-HNA antibody by EGIFA were positive for anti-HLA antibody.
CONCLUSION: EGIFA facilitated the measurement of anti-HNA-1a, -1b, and/or -2 antibodies in sera. The prompt measurement of anti-HNA antibodies will improve the diagnosis and clinical management of patients with suspected NAN or AIN.
C lassification of human neutrophil antigens (HNAs) was proposed at the Granulocyte Antigen Working Party of the International Society of Blood Transfusion in 1998. 1 In this classification, the HNA-1 system, which includes three alleles (HNA-1a, -1b, and -1c), is designated as CD16b (Fc gamma receptor IIIb [FccRIIIb]) [2] [3] [4] [5] and the HNA-2 system is designated as CD177. 2, 3, 6 Anti-HNA antibodies have been implicated in the development of immune neutropenias [7] [8] [9] [10] and transfusion-related acute lung injury.
or -2 antibodies are mainly detected in sera from Japanese patients with these clinical conditions. Several serologic methods can be used to detect anti-HNA antibodies, such as the granulocyte immunofluorescence test (GIFT), 14 the granulocyte agglutination test (GAT), 15 extracted granulocyte antigens by a mixed passive hemagglutination method, 16 and monoclonal antibody-specific immobilization of granulocyte antigens (MAIGA). 17, 18 Flow cytometry after GIFT, flow cytometry after the immunofluorescence test (IFT), 19 and GAT are generally used to detect anti-HNA antibodies in Japan. However, these methods require preparation of control HNAs by obtaining fresh granulocytes from healthy volunteers for each experiment because these control HNAs cannot be preserved for more than 1 day. Furthermore, it is not easy to prevent nonspecific antigen-antibody reactions because fresh granulocytes from healthy volunteers have several antigens, such as HLA antigens, on their cell surfaces. Therefore, a method that would enable clinicians to analyze multiple samples simultaneously with high sensitivity and specificity is required. We thus developed a MAIGA-modified method, which we refer to as the extracted granulocyte antigen immunofluorescence assay (EGIFA), using the Luminex system in the current study. We sought to preserve specific HNA antigens, which were extracted from KY cells, 20 for more than 8 months at 48C by immobilizing them with monoclonal antibody-conjugated microspheres (MoAb-microspheres). EGIFA enabled us to measure three different HNAs, HNA1a, -1b, and -2, simultaneously by using a mixture of 12 different MoAb/IgG 1 -microspheres. We evaluated the reliability of EGIFA by comparing it with traditional assay methods (GIFT, IFT, and MAIGA). Our results suggested that the specificity of EGIFA was comparable to that of MAIGA. Additionally, the sensitivity of EGIFA was higher than that of MAIGA and comparable to that of GIFT and IFT. We therefore recommend our new convenient and practical assay system, EGIFA, for rapid detection of anti-HNA-1a, -1b, and -2 antibodies in sera.
MATERIALS AND METHODS

Serum samples
Serum samples were obtained from healthy Japanese young adult volunteers (n 5 40), who provided their informed consent, and used as negative control sera. Serum samples from Japanese adult patients who received frequent blood transfusions (n 5 9) tested by GIFT were provided by the Department of Transfusion Medicine, University of Tokyo. Serum samples from Japanese neonates (younger than 28 days of age; n 5 10) with suspected neonatal alloimmune neutropenia (NAN) and their mothers (n 5 9) and serum samples from Japanese children (6 months to 5 years of age; n 5 88) with suspected autoimmune neutropenia (AIN) were also investigated. This study was approved by the ethics committee of Hiroshima University (Authorization No. 362).
EGIFA
Extraction of HNAs
We cultured HNA gene-transfected cell lines, KY-1a, KY1b, and KY-2a, in RPMI 1640 (Sigma-Aldrich) containing 10% fetal bovine serum, 2 mmol/L L-glutamine (SigmaAldrich), 100 mg/mL streptomycin (Gibco), 100 unit/mL penicillin (Gibco), and 0.5 mg/mL puromycin (Becton Dickinson) as previously described. 20 After cultured KY cells were washed twice with phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin (BSA; Sigma-Aldrich) and 0.1% NaN 3 (0.1% BSA-PBS), cells were suspended at 4 3 10 6 cells/mL in 0.9% NaCl containing 3% sucrose (sucrose-NaCl) for 72 hours at 48C, followed by the method described by Araki and colleagues. 16 After centrifugation at 800 3 g for 10 minutes at 48C, supernatants were concentrated using ultrafiltration (Centricut U10, filter for 10,000 Da; Kurabou Co.) to 1 mg protein/ mL concentration by centrifugation at 800 3 g at 48C.
Binding MoAbs to carboxylated microspheres 
Immobilizing of eHNAs with MoAb-microspheres
One-hundred microliters of eHNA-1a solution or eHNA1b solution was mixed with 10 mL of stock solution containing mIgG 1 -coated microspheres (mIgG 1 -microspheres) or the three types of CD16 MoAb-microspheres in a 1.5-mL tube (Table 1) . One-hundred microliters of eHNA-2 solution was also mixed with 10 mL of stock solution containing mIgG 1 -microspheres or the three types of CD177 MoAb-microspheres in a 1.5-mL tube. These reactions were performed for 2 hours at 48C by rotation. eHNA immobilized microspheres (eHNA-mIgG 1 -microspheres and eHNA-MoAb-microspheres) were then washed with PBS-TBN by centrifugation at 15,000 3 g for 5 minutes at 48C and resuspended in 500 mL of 1% BSA-PBS (final number of microspheres, 200/mL). We confirmed immobilization of eHNA-1a or -1b to CD16 MoAb-microspheres, and the absence of nonspecific immobilization of eHNAs to mIgG 1 -microspheres, using biotinylated anti-CD16 (polyclonal goat IgG; R&D Systems, Inc.) and RPE-conjugated streptavidin (Dako Cytomation). We also confirmed immobilization of eHNA-2 to CD177 MoAb-microspheres and the absence of nonspecific immobilization of eHNA-2 to mIgG 1 -microspheres, using RPE-labeled anti-CD177 (Clone 3H1954, United States Biological).
Testing of serum samples
One-hundred microliters of serum was mixed with 1 mL of mouse ascites (Institute of Immunology Co., Ltd.) for 30 minutes at 48C for absorption of human anti-mouse IgG antibodies. Serum samples were centrifuged at 15,000 3 g for 30 minutes at 48C to remove debris. Fifteen microliters of serum was then mixed with 45 mL of PBS-TBN containing 5% mouse normal serum (1:4 dilution; Millipore Corporation) in a 96-well microplate (MultiScreenHTS BV filter plate, 1.2 mm; Merck Millipore), followed by incubation with 1 mL of a mixed solution containing all eHNAMoAb/mIgG 1 -microspheres (200 microspheres/mL for each condition) for 30 minutes at room temperature by rotation. After being washed with PBS-TBN four times by filtering, the microspheres were reacted with RPEconjugated goat IgG F(ab 0 ) 2 anti-human IgG (H1L) (Jackson ImmunoResearch, Inc.) for 30 minutes at room temperature by rotation. After washing, the reactivity of sera was determined by Luminex 100 (Luminex Corp.). We calculated the relative fluorescence intensity (RFI) as follows: mean fluorescence intensity (MFI) of sample serum reaction with eHNA-MoAb-microspheres divided by MFI of sample serum reaction with eHNA-mIgG 1 -microspheres. We considered the reaction as positive when the RFI was greater than or equal to three times.
IFT
We obtained peripheral blood from two healthy volunteers with HNA-1a/1a (HNA-2 positive) neutrophils, two healthy volunteers with HNA-1b/1b (HNA-2 positive) neutrophils, and one healthy volunteer with HNA-1-null (HNA-2 positive) neutrophils. After being washed three times with 0.1% BSA-PBS, the whole blood was used for panel cells. We incubated 50 mL of whole blood with 25 mL of serum for 30 minutes at 48C. After elimination of red blood cells, cells were washed with 0.1% BSA-PBS and further incubated in the presence of FITC-conjugated goat IgG F(ab 0 ) 2 anti-human immunoglobulin (Invitrogen Corp.) for 30 minutes at 48C. The cells were then washed and analyzed by flow cytometry (FACSCalibur, Becton Dickinson). We calculated the RFI as follows: MFI of patient serum divided by MFI of negative control serum. Antibodies against granulocyte antigens were evaluated as positive when the RFI was greater than or equal to two times to not miss weak reactions for screening.
MAIGA
We performed MAIGA as previously described. 17 Briefly, peripheral blood containing EDTA-2Na was obtained from HNA-1a/1a type (HNA-2-positive) volunteers and HNA-1b/1b type (HNA-2 positive) volunteers. Separated granulocytes were fixed with 1% paraformaldehyde. After being washed three times with cell wash buffer (PBS containing 0.2% BSA and 0.1% NaN 3 ) by centrifugation, 1 3 10 6 granulocytes were plated in each well in a 96-well Ubottom microplate. After removal of supernatant by centrifugation, granulocytes were incubated with 50 mL of sample serum for 30 minutes at 378C. After being washed, granulocytes were then incubated with 40 mL of MoAb (5 mg/mL concentration) for 30 minutes at 378C. We used 3G8 and LNK16 to detect CD16, and TAG4 and 7D8, or MEM166 to detect CD177. After being washed, granulocytes were solubilized with 100 mL/well lysis buffer (10 mmol/L Tris [pH 7.4], 0.5% Nonidet P-40 [Sigma-Aldrich], 50 mmol/L CaCl 2 , 0.9% NaCl, 1 mmol/L phenylmethylsulfonyl fluoride [Sigma-Aldrich], and 10 mL/mL protease inhibitor cocktail [Sigma-Aldrich]) for 30 minutes at 48C followed by sonication for 1 minute. Lysates were then centrifuged (500 3 g for 30 min at 48C) and supernatants were collected. Before analysis of the lysates, wells of a 96-well microplate were coated with 100 mL of 3 mg/mL goat anti-mouse IgG (Invitrogen Corp.) in 0.05 mol/L carbonate buffer (pH 9.6) and incubated overnight at 48C. After the wells were washed and blocked, 100 mL of lysate was added to the wells and incubated for 90 minutes at 48C. After washing, alkaline phosphatase-conjugated goat antihuman IgG (1:10,000 dilution; Southern Biotech) was added and incubated for 2 hours at 48C. After washing, 100 mL of 1,2-phenylenediamine substrate buffer (pH 9.8; Sigma-Aldrich) was then added and incubated for 30 minutes at 378C. The reaction was then stopped by addition of 100 mL of 3 N NaOH solution and read at an absorbance of 405 nm. Blank corrections were performed using Tween wash buffer. We calculated the relative optical density (ROD) as follows: OD of sample serum divided by OD of negative control serum. Background OD (mean of four blanks) was removed before ROD calculation. We considered the reaction as positive when the ROD was greater than or equal to three times.
Analysis of anti-HLA antibody
Anti-HLA Class I IgG antibodies were measured in neonates and children using the HLA typing kit (Wakunaga Pharmaceutical Co., Ltd.) following the manufacturer's instructions.
RESULTS
Antigenicity of eHNA can be preserved for at least 8 months at 48C
We first investigated the storage stability of the stock solutions containing eHNA-MoAb/mIgG 1 -microspheres at 48C. The antigenicity of eHNA-1a gradually decreased over time, whereas no obvious loss of antigenicity was observed in eHNA-1b and eHNA-2 for at least 15 months. However, more than 80% antigenicity of all three antigens was preserved at 8 months (Table S1 , available as supporting information in the online version of this paper). These results suggest that eHNAMoAb/mIgG 1 -microspheres can be stored for at least 8 months at 48C.
Cutoff value of positive reactions
We then investigated the reactivity to eHNA-MoAbmicrospheres in sera from 40 healthy volunteers. Figure 1 and Tables S2, S4 , and S5 (available as supporting information in the online version of this paper) summarize the RFIs of sera from healthy volunteers, neonates with suspected NAN, and children with suspected AIN. The distribution of the mean RFI value detected by nine different eHNA-microspheres ranged from 0.5 to 1.1 in sera from 40 healthy volunteers (standard deviation, 0.1-0.7; Table  S2 ). Based on the RFI distribution, we considered the reaction as positive when the RFI was greater than or equal to three times. and children (n 5 88) with AIN. The reaction is considered to be positive when the RFI is greater than or equal to three times.
Assessment of EGIFA
We assessed the ability of EGIFA to detect anti-HNA antibodies using serum samples from nine adult patients. The presence of anti-HNA antibodies in these samples was confirmed by GIFT in prior experiments. We measured anti-HNA antibodies in these samples by EGIFA, MAIGA, and IFT (Table 2, Table S3 ). Due to limited sample availability, we could not test Sample 9 by MAIGA. EGIFA successfully detected anti-HNA antibodies in all nine serum samples. When we compared the results of detected anti-HNA antibodies, there was no discrepancy between EGIFA, GIFT, and MAIGA. Anti-HNA-2 antibodies reacted with HNA-1a/1a, -1b/1b, and/or -1-null panel cells by IFT because control granulocytes used for HNA-1a/1a, -1b/1b and -1-null panel cells express HNA-2 antigen.
Next, we investigated anti-HNA antibodies in sera from familial cases with suspected NAN (Table 3, Table  S4 ). EGIFA successfully identified the same type of anti-HNA antibody in seven of nine families, suggesting that this method can accurately detect maternal anti-HNA antibody in neonates with NAN. Additionally, EGIFA successfully detected maternal anti-HNA-1a antibody in Sample 1 (Family A) and Sample 7 (Family D), whereas IFT failed to detect them. In contrast, EGIFA failed to detect any anti-HNA antibody in Family I (sample Nos. [17] [18] [19] , whereas IFT showed positive reaction to HNA-1a/ 1a panel cells in this family. The presence of anti-HNA antibody was identified only in six samples (Samples 2, 3, 8, 9, 12, and 14) by MAIGA. However, the results of these six samples were in agreement with the results of EGIFA. Application of EGIFA for detection of anti-HNA antibodies in sera from children with suspected AIN
We further applied EGIFA for detection of anti-HNA antibodies in sera from children (aged 6 months to 5 years; n 5 88) with suspected AIN (Fig. 2A , Table S5 ). The presence of isolated anti-HNA-1a or -1b antibodies was identified in 4.5% (four of 88) or 12.5% (13 of 88) of children, respectively. Moreover, the coexistence of anti-HNA-1a and -1b antibodies was identified in 20.5% (18 of 88) of these children, suggesting the existence of two different antibodies or autoantibodies against an isoantigen of FccRIIIb. The presence of anti-HNA-2 antibody was identified in 3.4% (three of 88) of the children, while no anti-HNA-2 antibody was detected in neonates. Approximately 36.1% (13 of 36) of children who had anti-HNA antibody also had anti-HLA antibody (Fig. 2B , Table S6 , available as supporting information in the online version of this paper).
DISCUSSION
In this study, we developed a new method, EGIFA, to detect anti-HNA-1a, -1b, and -2 antibodies simultaneously. We focused on anti-HNA-1a, -1b, and -2 antibodies because the majority of anti-HNA antibodies detected in Japanese patients with immune neutropenias are anti-HNA-1a, -1b, or -2 based on the frequency of HNA types in Japan. 13 To evaluate the reliability of EGIFA, we compared the results of EGIFA with the results obtained from several conventional methods. We investigated serum samples from nine patients positive for anti-HNA-1a, -1b, or -2 antibody by GIFT. MAIGA is known to have high specificity and has been used as a confirmatory test. In this study, all anti-HNA antibodies detected by MAIGA were reproducibly detected by EGIFA. Moreover, EGIFA, as well as GIFT, detected several anti-HNA antibodies that MAIGA failed to detect. These results suggested that EGIFA has equivalent specificity and superior sensitivity compared with MAIGA in the analysis of anti-HNA-1a, -1b, and -2 antibodies. Both GIFT and IFT are methods with high sensitivity and have been used for screening and confirmation of anti-HNA antibodies. Notably, EGIFA successfully detected anti-HNA antibody in two serum samples from neonates with suspected NAN that IFT failed to detect (Table 3) . Conversely, EGIFA failed to detect anti-HNA antibody in Family I, whereas IFT demonstrated reaction with HNA-1a/1a panel cells. It is well known that HNA types of positive panel cells do not always indicate antibody specificity in IFT. Thus, this observation might be explained by the presence of another anti-neutrophil antibody, excluding anti-HNA-1a, -1b, and -2 antibodies, that reacted with antigens on the panel cells in IFT. Indeed, we detected anti-HLA-I antibody in Family I. Although one limitation of EGIFA is its narrow detection range of anti-neutrophil antibodies, it demonstrated high sensitivity against anti-HNA-1a, -1b, and -2 antibodies that was comparable to GIFT and IFT and high specificity that was comparable to MAIGA. The conventional assay methods GIFT, IFT, MAIGA, and GAT require control HNAs in each experiment, which are obtained by collecting blood samples from multiple healthy volunteers. Since neutrophils contain several surface antigens, control antigens derived from neutrophils have the potential to react not only with specific anti-HNA antibodies, but also with other antibodies such as anti-HLA antibodies. Therefore, the reaction of HNA type of panel neutrophils to serum samples does not directly indicate a specific reaction to HNA. The development of IFT using KY cell lines (KY-IFT) resolved the requirement of neutrophils from multiple healthy donors and improved the specificity by eliminating contamination by other antigens expressed by neutrophils. However, in the current study, KY-IFT appeared to have reduced sensitivity of anti-HNA antibody detection. EGIFA dramatically improved the sensitivity by concentrating HNAs extracted from KY cells. Moreover, EGIFA has two additional advantages to the conventional methods. First, EGIFA does not require preparation of control HNAs for each experiment. The antigenicity of HNAs was preserved for more than 8 months at 48C by preparing eHNA-MoAb/mIgG 1 -microspheres. This improvement allows clinicians to measure anti-HNA antibody on demand. Second, EGIFA enabled us to measure three different HNAs, HNA-1a, -1b, and -2, simultaneously using only 15 mL of serum with the mixture of 12 different MoAb/IgG 1 -microspheres. EGIFA also enabled us to evaluate many serum samples simultaneously. In contrast, large volumes of serum were needed to obtain similar results using GIFT, IFT, and MAIGA. This advantage is especially beneficial for cases in which serum collection is difficult, such as neonates and infants.
A microbead multiplex assay, LABScreen MULTI (One Lambda), to detect granulocyte antibodies has recently become commercially available. [21] [22] [23] The primary advantage of LABScreen MULTI compared to EGIFA is its ability to detect multiple anti-granulocyte antigens (i.e., anti-HNA-1a, -1b, -2, -3a, -3b, -4a, -5a, and -5b) and anti-HLA Class I and II antibodies simultaneously. Previous studies suggested that LABScreen MULTI has relatively high sensitivity and specificity. 22, 23 However, the reliability of LABScreen MULTI might be inferior to MAIGA in the detection of anti-HNA antibody. 22 It also has the possible risk of false-positive reactions for HNA-2 beads. 23 In contrast, in the current study, EGIFA demonstrated high sensitivity against anti-HNA-1a, -1b, and -2 antibodies that was comparable to GIFT and IFT and high specificity that was comparable to MAIGA. The detection of anti-HNA antibody has the potential to change the clinical management of patients with immune neutropenias. G-CSF therapy is an effective treatment option for patients with immune neutropenias due to anti-HNA-1a and/or -1b antibody or antibody against an isoantigen of FccRIIIb. However, its use should be carefully considered in patients with anti-HNA-2 antibody. In some cases, the administration of G-CSF exacerbates neutropenia by up regulating HNA-2 antigen expression at the neutrophil surface.
25,26 Therefore, the prompt measurement of anti-HNA-2 antibody is beneficial not only for a definitive diagnosis, but also for better clinical management of patients with immune neutropenia. In this study, EGIFA successfully detected AIN associated with anti-HNA-2 antibody in 3.4% of children with suspected AIN, suggesting that EGIFA has the potential to improve clinical management by providing prompt measurement of anti-HNA-2 antibody. However, there are some limitations associated with EGIFA. First, EGIFA developed in this study can only detect anti-HNA-1a, -1b, and -2 antibodies. Therefore, it would not detect anti-HNA antibody if the patient developed AIN associated with other anti-HNA antibodies. To overcome this limitation, we are currently developing MoAb-microspheres to detect other anti-HNA antibodies. Second, EGIFA also fails to detect immune neutropenias associated with anti-HLA antibodies. Third, it is possible that HNA antigenicity is altered during eHNA-MoAb-microsphere preparation. Indeed, Araki and coworkers 16 reported that some antibodies reacted strongly to intact granulocytes but weakly to granulocyte antigens extracted with sucrose-NaCl. However, considering the high sensitivity and specificity of EGIFA observed in this study, any reduction in HNA antigenicity may be negligible.
In conclusion, we developed a new convenient and practical assay system, EGIFA, to assess anti-HNA-1a, -1b, and -2 antibodies in human sera with high sensitivity and specificity. EGIFA will enable clinicians to test and identify antibody specificity in many samples simultaneously while requiring little serum volume, making it particularly appealing for use in neonates and children. 
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